Emmaus Sickle Cell NDA Facing FDA Concerns About Clinical Meaningfulness

PGLG's application only has one Phase III trial, and Emmaus is hoping statistical re-analyses can address FDA skepticism about clinical meaningfulness of the primary endpoint data.

Emmaus Life Sciences Inc. is counting on new statistical analyses and secondary endpoints to resolve FDA's concerns about the single Phase III trial submitted with the new drug application for the company's pharmaceutical-grade L-glutamine (PGLG) to treat sickle cell disease.

The product could be a landmark in a disease with significant unmet need – Emmaus emphasizes that PGLG would be...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet